Bayer and Nektar Collaborate on Inhaled Pneumonia Drug
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 87 (Table of Contents)
Published: 7 Sep-2007
DOI: 10.3833/pdr.v2007.i87.286 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bayer HealthCare and Nektar Therapeutics have agreed to develop and commercialize NKTR-061 (inhaled amikacin) for adjunctive treatment of ventilated patients with hospital-acquired Gram-negative pneumonias...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS